RT Journal Article
T1 A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group.
A1 Pardal, Emilia
A1 Diez-Baeza, Eva
A1 Salas, Queralt
A1 Garcia, Tomas
A1 Sancho, Juan M
A1 Monzon, Encarna
A1 Moraleda, Jose M
A1 Cordoba, Raul
A1 de-la-Cruz, Fatima
A1 Queizan, Jose A
A1 Rodriguez, Maria J
A1 Navarro, Belen
A1 Hernandez, Jose A
A1 Diez, Rosana
A1 Vahi, Maria
A1 Viguria, Maria C
A1 Canales, Miguel
A1 Peñarrubia, Maria J
A1 Gonzalez-Lopez, Tomas J
A1 Montes-Moreno, Santiago
A1 Gonzalez-Barca, Eva
A1 Caballero, Dolores
A1 Martín, Alejandro
K1 Cyclophosphamide
K1 Doxorubicin
K1 Lymphoma, Large B-Cell, Diffuse
K1 Prednisone
K1 Rituximab
K1 Spain
AB The means of optimally managing very elderly patients with diffuse large B-cell lymphoma (DLBCL) has not been established. We retrospectively analyzed 252 patients aged 80-100 years, diagnosed with DLBCL or grade 3B follicular lymphoma, treated in 19 hospitals from the GELTAMO group. Primary objective was to analyze the influence of the type of treatment and comorbidity scales on progression-free survival (PFS) and overall survival (OS). One hundred sixty-three patients (63%) were treated with chemotherapy that included anthracyclines and/or rituximab, whereas 15% received no chemotherapeutic treatment. With a median follow-up of 44 months, median PFS and OS were 9.5 and 12.5 months, respectively. In an analysis restricted to the 205 patients treated with any kind of chemotherapy, comorbidity scales did not influence the choice of treatment type significantly. Independent factors associated with better PFS and OS were: age  85 years, R-IPI 3-5 or CIRS > 5). In conclusion, treatment with R-CHOP-like is associated with good survival in a significant proportion of patients. We have developed a simple prognostic model that may aid the selection patients who could benefit from a curative treatment, although it needs to be validated in larger series.
PB John Wiley & Sons, Inc.
YR 2018
FD 2018-07-09
LK http://hdl.handle.net/10668/12352
UL http://hdl.handle.net/10668/12352
LA en
NO Pardal E, Díez Baeza E, Salas Q, García T, Sancho JM, Monzón E, et al. A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group. Am J Hematol. 2018 Jul;93(7):867-873.
NO This work was supported in part (histopathological review) by grants from the Ministerio de Economía, Industria y Competitividad (RD12/0036/0060) and Instituto de Investigación Sanitaria de Valdecilla (NVAL15/09). Our appreciation goes to Mónica Sánchez for monitoring the study, and Tomás Serrano, for the logistic support.
DS RISalud
RD Apr 17, 2025